Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia

Targeted therapies including the engineered afucosylated anti-CD20 monoclonal antibody obinutuzumab, Bruton’s tyrosine kinase inhibitor ibrutinib, and B-cell lymphoma protein 2 inhibitor venetoclax have demonstrated significant clinical activity in chronic lymphocytic leukemia (CLL) and, based on th...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood
Autori principali: Rogers, Kerry A., Huang, Ying, Ruppert, Amy S., Awan, Farrukh T., Heerema, Nyla A., Hoffman, Corinne, Lozanski, Gerard, Maddocks, Kami J., Moran, Mollie E., Reid, Mark A., Lucas, Margaret, Woyach, Jennifer A., Whitlow, W. Thomas, Jones, Jeffrey A., Byrd, John C.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2018
Soggetti:
Clinical Trials and Observations
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6182267/
https://ncbi.nlm.nih.gov/pubmed/30111609
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-05-853564
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi